US FDA requires boxed warning and REMS for botulinum toxin products
This article was originally published in SRA
Prompted by reports of serious adverse events, the US Food and Drug Administration is requiring safety labelling changes, including a boxed warning, and a Risk Evaluation and Mitigation Strategy, for all botulinum toxin products1. Manufacturers are required to submit the requested safety labelling changes, including the boxed warning and a Medication Guide, to the FDA by the end of May, or to provide a reason why they do not believe such changes are necessary.
You may also be interested in...
In this week’s podcast, Medtech Insight's managing editor Marion Webb has an update from the virtual HLTH panel discussions on telehealth and robotics. Deputy editor Reed Miller discusses trial results from Boston Scientific’s next-generation Accurate neo2 self-expanding aortic valve presented during the Transcatheter Cardiovascular Therapeutics (TCT) meeting.
The rare disease-focused firm will pay $90m up front to acquire Orphan Technologies and its Phase I/II enzyme replacement therapy for homocystinuria. Earnouts up to $427m are possible as well.